in

Swedish biopharmaceutical company: Calliditas Therapeutics (CALT)

Calliditas Therapeutics AB (NASDAQ: CALT) was founded in 2004 and is headquartered in Stockholm, Sweden. It has 24 full-time employees. It is a clinical-stage biopharmaceutical company dedicated to identifying, developing and commercializing orphan indications The initial focus is on kidney and liver diseases with unmet medical needs.

Calliditas Therapeutics

Calliditas Therapeutics AB (CALT):

Calliditas Therapeutics was established in 2004 with the purpose of developing and commercializing Nefecon. Nefecon was purchased from its inventors, Professor Bengt Fellström and Professor Roger Hällgren of Uppsala University in Sweden.

Calliditas is led by an experienced and dedicated management team with an average of more than 15 years of prior experience in the pharmaceutical industry, including leading pharmaceutical companies such as GlaxoSmithKline , Novo Nordisk , Pfizer and UCB. The board of directors includes highly qualified researchers, pharmaceutical industry executives, and experts in the fields of drug development, corporate development and drug commercialization. Calliditas is highly supported by a network of well-known experts in the IgAN field, including well-known IgAN experts from all over the world, who are all external consultants and researchers for Nefecon clinical trials.

The main drug candidate of Calliditas Therapeutics-Nefecon, is a novel and proprietary oral formulation of budesonide. Budesonide is an established and highly effective local immunosuppressant for the treatment of autoimmunity Nephropathy IgA nephropathy (IgAN), IgAN treatment needs are highly unmet, and there are currently no approved therapies.

IgAN is a progressive chronic disease that can cause deterioration of kidney function in patients over time. Many of them are ultimately at risk of developing end-stage renal disease (ESRD) and require dialysis or kidney transplantation.

Nefecon is currently the only drug candidate that is expected to change the disease in the development of IgAN. Nefecon targets the ileum, the distal region of the small intestine, which is a presumed source of IgAN because the ileum is where the highest concentration of Peyer’s plaques are located, which are responsible for the production of secretory immunoglobulin A (IgA) antibodies. Nefecon has obtained orphan drug rights for the treatment of IgAN in the United States and the European Union.

Calliditas Therapeutics AB (CALT) investment:

The common stock of Calliditas Therapeutics is traded on Nasdaq Stockholm under the ticker symbol “CALTX”. On May 28, 2020, the closing price of the company’s shares in Nasdaq Stockholm was 94.00 Swedish Krona per share, which is equivalent to 19.77 US dollars per ADS based on the exchange rate of SEK/US.

Calliditas Therapeutics AB (NASDAQ: CALT), a company called Calliditas Therapeutics AB (NASDAQ: CALT), was listed on NASDAQ on 6/5/2020, with an issue price of US$19.5, issuing 7.6 million shares, raising US$148.2 million, and underwriting by Citigroup/ Jefferies/ Stifel.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

China Stocks: Ucloudlink Group Inc (UCL), a mobile data sharing platform

UntitlClinical stage biotechnology company: Lantern Pharma Inc. (LTRN)ed document